BiotechTube

Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo

Phase 3Terminated
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Intraocular Lens Replacement

Conditions

Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome

Trial Timeline

Feb 1, 2014 → Aug 1, 2014

NCT ID
NCT02093689

About Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo

Part 1 OMS302 + Part 2 OMS302 + Part 2 Placebo is a phase 3 stage product being developed by Omeros Corporation for Intraocular Lens Replacement. The current trial status is terminated. This product is registered under clinical trial identifier NCT02093689. Target conditions include Intraocular Lens Replacement, Intraoperative Floppy Iris Syndrome.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02093689Phase 3Terminated

Competing Products

6 competing products in Intraocular Lens Replacement

See all competitors
ProductCompanyStageHype Score
Mirabegron + PlaceboAstellas PharmaPhase 1
33
AZD4017 + Placebo + AZD4017 + PlaceboAstraZenecaPhase 2
52
ipilimumab + Tyrosinase/gp100/MART-1 PeptidesBristol Myers SquibbPhase 2
51
OMS302 + PlaceboOmeros CorporationPhase 3
72
OMS302 + PlaceboOmeros CorporationPhase 3
72
cisplatin + sunitinib malate + tamoxifen citratePacific BiosciencesPhase 2
44

Other Products from Omeros Corporation

1% preservative-free lidocaine + Phenylephrine 1.0%/ Ketorolac 0.3%Approved
80
OmidriaApproved
80
OMS302 + PlaceboPhase 3
72
OMS103HP + VehiclePhase 3
72
OMS103HP + VehiclePhase 3
72